Rheumatoid Arthritis Clinical Trials in New York

Showing 1841-1860 of 3,596 trials

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

NCT03439280

The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone (PomDex) in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-079 monotherapy in Phase 2a in participants with r/r MM.

Relapsed/RefractoryMultiple Myeloma

Millennium Pharmaceuticals, Inc.50 participantsStarted Apr 2018

Duarte, California, United States • St Louis, Missouri, United States • New York, New York, United States +4 more locations

COMPLETEDPhase 1< 1 mile

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

NCT04862741

This is a Phase 1b, randomized, double-blind, multicenter dose-ranging study to evaluate the safety, tolerability, and PK of NX-13. Approximately 40 subjects will be randomized in a 3:3:3:1 ratio to receive 1 of 3 NX-13 treatment regimens (NX-13 250 mg IR, 500 mg IR, 500 mg MR) (12 evaluable subjects at each of the 3 dose levels) or placebo (4 subjects), once daily for 28 consecutive days.

Ulcerative Colitis

Landos Biopharma Inc.39 participantsStarted May 2021

Huntsville, Alabama, United States • Lancaster, California, United States • Mission Viejo, California, United States +28 more locations

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Rheumatoid Arthritis Trials in Other Cities

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

MPN-RC 118 AVID200 in Myelofibrosis

Expanding PrEP By Embedding Unannounced SNAPS Navigators in High STI Testing Clinical Sites

Higher Irradiance in Keratoconus Ectasia

Characterization & Treatment of Chronic Pain After Moderate to Severe TBI

Long-term Cardiac Monitoring in Epilepsy

Comparison Of Effective Radiation Shielding Between Rampart IC, M1128 Shield vs Conventional Apron And Shields In Clinical Interventional Procedures

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

Trial in Adult Subjects With Acute Migraines

Safety and Efficacy in Adult Subjects With Acute Migraines

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)

Thoracolumbar Burst Fractures Study Comparing Surgical Versus Non-surgical Treatment

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Microarray Expression Profiling to Identify Stereotypic mRNA Profiles in Human Parturition

Other Conditions in New York